Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Mannkind Corp (MNKD)

Mannkind Corp (MNKD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,007,190
  • Shares Outstanding, K 307,070
  • Annual Sales, $ 285,500 K
  • Annual Income, $ 27,590 K
  • EBIT $ 73 M
  • EBITDA $ 84 M
  • 60-Month Beta 0.84
  • Price/Sales 2.89
  • Price/Cash Flow 23.63
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 108.57% (+4.68%)
  • Historical Volatility 141.75%
  • IV Percentile 31%
  • IV Rank 15.12%
  • IV High 500.78% on 10/09/25
  • IV Low 38.72% on 04/01/25
  • Expected Move (DTE 5) 0.43 (12.96%)
  • Put/Call Vol Ratio 0.11
  • Today's Volume 1,525
  • Volume Avg (30-Day) 2,121
  • Put/Call OI Ratio 0.23
  • Today's Open Interest 67,403
  • Open Int (30-Day) 62,033
  • Expected Range 2.86 to 3.71

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.05
  • Number of Estimates 1
  • High Estimate -0.05
  • Low Estimate -0.05
  • Prior Year 0.04
  • Growth Rate Est. (year over year) -225.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.93 +11.75%
on 02/26/26
6.27 -47.69%
on 02/04/26
-2.31 (-41.32%)
since 01/27/26
3-Month
2.93 +11.75%
on 02/26/26
6.51 -49.62%
on 01/08/26
-2.10 (-39.03%)
since 11/26/25
52-Week
2.93 +11.75%
on 02/26/26
6.51 -49.62%
on 01/08/26
-1.95 (-37.28%)
since 02/27/25

Most Recent Stories

More News
MannKind: Q4 Earnings Snapshot

MannKind: Q4 Earnings Snapshot

MNKD : 3.28 (+1.23%)
MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Q4 2025 revenues of $112M, +46% vs. Q4 2024 Furoscix ® Q4 2025 net sales of $23M, +91% vs. Q4 2024 Afrezza ® Q4 2025 net sales of $23M, +25% vs. Q4 2024 2025 full year revenues...

MNKD : 3.28 (+1.23%)
MannKind to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , today announced Chief Executive Officer Michael Castagna, PharmD is scheduled...

MNKD : 3.28 (+1.23%)
MannKind to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a biopharmaceutical company dedicated to transforming chronic disease care through...

MNKD : 3.28 (+1.23%)
MannKind Announces First Patient Enrolled in INHALE-1ST Pediatric Study Evaluating Afrezza® for Youth with Newly-Diagnosed Type 1 Diabetes (T1D)

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a biopharmaceutical company dedicated to transforming chronic disease care through...

MNKD : 3.28 (+1.23%)
MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy

Updated initial conversion table based on clinical trials in adults showing significantly improved mealtime glycemic excursions DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 26, 2026 (GLOBE...

MNKD : 3.28 (+1.23%)
MannKind Provides Business Updates and 2026 Growth Drivers

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a biopharmaceutical company dedicated to transforming chronic disease care through...

MNKD : 3.28 (+1.23%)
MannKind Shares FUROSCIX® Business Updates

FDA approves FUROSCIX ® for use in pediatric patients weighing 43kg or above USPTO issues five patents for FUROSCIX ReadyFlow ™ Autoinjector WESTLAKE VILLAGE, Calif. and BURLINGTON,...

MNKD : 3.28 (+1.23%)
MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease

If approved, ReadyFlow Autoinjector would deliver an IV-equivalent diuretic dose (subcutaneous furosemide injection 80 mg/ml) in under 10 seconds Would potentially provide a cost-effective and convenient...

MNKD : 3.28 (+1.23%)
MannKind to Present at the Jefferies Global Healthcare Conference

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD ) announced today that Michael Castagna, Chief Executive Officer, and Chris Prentiss,...

MNKD : 3.28 (+1.23%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Average short term outlook on maintaining the current direction.

Relative Strength is below 20%. The market is in extreme oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Mannkind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes, cancer, inflammatory and autoimmune diseases. The Company's lead product, the Technosphere Insulin System, consists of the Company's dry-powder...

See More

Key Turning Points

3rd Resistance Point 3.61
2nd Resistance Point 3.49
1st Resistance Point 3.39
Last Price 3.28
1st Support Level 3.16
2nd Support Level 3.04
3rd Support Level 2.93

See More

52-Week High 6.51
Fibonacci 61.8% 5.14
Fibonacci 50% 4.72
Fibonacci 38.2% 4.30
Last Price 3.28
52-Week Low 2.93

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar